Solid Tumors Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major solid tumors markets reached a value of US$ 170.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 375.4 Billion by 2034, exhibiting a growth rate (CAGR) of 7.45% during 2024-2034.
The solid tumors market has been comprehensively analyzed in IMARC's new report titled "Solid Tumors Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A solid tumor refers to a type of abnormal growth or mass formed by the uncontrolled proliferation of cells in a specific tissue or organ. This condition can be either benign or malignant. Benign tumors are non-cancerous and they often have well-defined borders, whereas malignant tumors are cancerous and have the potential to invade nearby tissues and spread to distant organs through a process known as metastasis. Some common symptoms associated with the illness include the presence of a palpable lump or mass, pain, discomfort, changes in bowel or bladder habits, fatigue, unexplained weight loss, indigestion, nausea, vomiting, persistent cough, difficulty swallowing, etc. Diagnosing solid tumors typically involves a combination of medical history evaluation, clinical feature assessment, and physical examination. Several imaging techniques, like positron emission tomography (PET) scans, ultrasounds, X-rays, etc., are also utilized to detect metabolic activity in cells and identify possible areas of cancer. In addition to this, the healthcare provider may perform a tissue biopsy, followed by laboratory tests, to determine the specific type and grade of the tumor.
The increasing cases of genetic mutations or inherited conditions, which can disrupt normal cell growth and division, leading to uncontrolled cell proliferation, are primarily driving the solid tumors market. In addition to this, the rising incidences of numerous associated risk factors, including exposure to tobacco smoke, viral infections, chronic inflammation, advancing age, hormonal imbalance, obesity, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapy drugs, such as dabrafenib mesylate, larotrectinib sulfate, pembrolizumab, etc., for reducing the symptoms of the ailment is further bolstering the market growth. These agents help to treat tumors by interfering with specific molecules or proteins that cause cancer to grow and spread throughout the body. Apart from this, the inflating application of angiogenesis inhibitors which prevent the formation of new blood vessels, thereby restricting blood supply to the tumor, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiotherapy, owing to its several benefits, such as non-invasiveness, effective tumor control, preservation of organ function, etc., is expected to drive the solid tumors market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the solid tumors market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for solid tumors and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the solid tumors market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the solid tumors market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the solid tumors market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current solid tumors marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the solid tumors market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the solid tumors market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the solid tumors market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of solid tumors across the seven major markets?
What is the number of prevalent cases (2018-2034) of solid tumors by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of solid tumors by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with solid tumors across the seven major markets?
What is the size of the solid tumors patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of solid tumors?
What will be the growth rate of patients across the seven major markets?
Solid Tumors: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for solid tumors drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the solid tumors market?
What are the key regulatory events related to the solid tumors market?
What is the structure of clinical trial landscape by status related to the solid tumors market?
What is the structure of clinical trial landscape by phase related to the solid tumors market?
What is the structure of clinical trial landscape by route of administration related to the solid tumors market?
The solid tumors market has been comprehensively analyzed in IMARC's new report titled "Solid Tumors Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A solid tumor refers to a type of abnormal growth or mass formed by the uncontrolled proliferation of cells in a specific tissue or organ. This condition can be either benign or malignant. Benign tumors are non-cancerous and they often have well-defined borders, whereas malignant tumors are cancerous and have the potential to invade nearby tissues and spread to distant organs through a process known as metastasis. Some common symptoms associated with the illness include the presence of a palpable lump or mass, pain, discomfort, changes in bowel or bladder habits, fatigue, unexplained weight loss, indigestion, nausea, vomiting, persistent cough, difficulty swallowing, etc. Diagnosing solid tumors typically involves a combination of medical history evaluation, clinical feature assessment, and physical examination. Several imaging techniques, like positron emission tomography (PET) scans, ultrasounds, X-rays, etc., are also utilized to detect metabolic activity in cells and identify possible areas of cancer. In addition to this, the healthcare provider may perform a tissue biopsy, followed by laboratory tests, to determine the specific type and grade of the tumor.
The increasing cases of genetic mutations or inherited conditions, which can disrupt normal cell growth and division, leading to uncontrolled cell proliferation, are primarily driving the solid tumors market. In addition to this, the rising incidences of numerous associated risk factors, including exposure to tobacco smoke, viral infections, chronic inflammation, advancing age, hormonal imbalance, obesity, etc., are creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapy drugs, such as dabrafenib mesylate, larotrectinib sulfate, pembrolizumab, etc., for reducing the symptoms of the ailment is further bolstering the market growth. These agents help to treat tumors by interfering with specific molecules or proteins that cause cancer to grow and spread throughout the body. Apart from this, the inflating application of angiogenesis inhibitors which prevent the formation of new blood vessels, thereby restricting blood supply to the tumor, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiotherapy, owing to its several benefits, such as non-invasiveness, effective tumor control, preservation of organ function, etc., is expected to drive the solid tumors market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the solid tumors market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for solid tumors and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the solid tumors market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the solid tumors market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the solid tumors market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current solid tumors marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the solid tumors market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the solid tumors market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the solid tumors market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of solid tumors across the seven major markets?
What is the number of prevalent cases (2018-2034) of solid tumors by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of solid tumors by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with solid tumors across the seven major markets?
What is the size of the solid tumors patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of solid tumors?
What will be the growth rate of patients across the seven major markets?
Solid Tumors: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for solid tumors drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the solid tumors market?
What are the key regulatory events related to the solid tumors market?
What is the structure of clinical trial landscape by status related to the solid tumors market?
What is the structure of clinical trial landscape by phase related to the solid tumors market?
What is the structure of clinical trial landscape by route of administration related to the solid tumors market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOLID TUMORS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SOLID TUMORS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SOLID TUMORS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SOLID TUMORS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SOLID TUMORS - UNMET NEEDS
10 SOLID TUMORS - KEY ENDPOINTS OF TREATMENT
11 SOLID TUMORS - MARKETED PRODUCTS
11.1 List of Solid Tumors Marketed Drugs Across the Top 7 Markets
11.1.1 Vitrakvi (Larotrectinib) - Bayer/Loxo Oncology
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Xgeva (Denosumab) - Amgen
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Retevmo (Selpercatinib) - Loxo oncology
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Keytruda (Pembrolizumab) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SOLID TUMORS - PIPELINE DRUGS
12.1 List of Solid Tumors Pipeline Drugs Across the Top 7 Markets
12.1.1 RMC 4630 - REVOLUTION Medicine
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AZD 9592 - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ceralasertib - AstraZeneca
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PRL3-zumab - Intra-Immusg
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CPO 100 - Conjupro Biotherapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SOLID TUMORS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SOLID TUMORS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SOLID TUMORS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Solid Tumors - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Solid Tumors - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Solid Tumors - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Solid Tumors - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Solid Tumors - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Solid Tumors - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Solid Tumors - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Solid Tumors - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Solid Tumors - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Solid Tumors - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Solid Tumors - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Solid Tumors - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Solid Tumors - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Solid Tumors - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Solid Tumors - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Solid Tumors - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Solid Tumors - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Solid Tumors - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Solid Tumors - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Solid Tumors - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Solid Tumors - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Solid Tumors - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Solid Tumors - Access and Reimbursement Overview
16 SOLID TUMORS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SOLID TUMORS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SOLID TUMORS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOLID TUMORS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SOLID TUMORS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SOLID TUMORS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SOLID TUMORS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SOLID TUMORS - UNMET NEEDS
10 SOLID TUMORS - KEY ENDPOINTS OF TREATMENT
11 SOLID TUMORS - MARKETED PRODUCTS
11.1 List of Solid Tumors Marketed Drugs Across the Top 7 Markets
11.1.1 Vitrakvi (Larotrectinib) - Bayer/Loxo Oncology
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Xgeva (Denosumab) - Amgen
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Retevmo (Selpercatinib) - Loxo oncology
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Keytruda (Pembrolizumab) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SOLID TUMORS - PIPELINE DRUGS
12.1 List of Solid Tumors Pipeline Drugs Across the Top 7 Markets
12.1.1 RMC 4630 - REVOLUTION Medicine
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AZD 9592 - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ceralasertib - AstraZeneca
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PRL3-zumab - Intra-Immusg
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CPO 100 - Conjupro Biotherapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SOLID TUMORS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SOLID TUMORS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SOLID TUMORS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Solid Tumors - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Solid Tumors - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Solid Tumors - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Solid Tumors - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Solid Tumors - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Solid Tumors - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Solid Tumors - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Solid Tumors - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Solid Tumors - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Solid Tumors - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Solid Tumors - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Solid Tumors - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Solid Tumors - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Solid Tumors - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Solid Tumors - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Solid Tumors - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Solid Tumors - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Solid Tumors - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Solid Tumors - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Solid Tumors - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Solid Tumors - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Solid Tumors - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Solid Tumors - Access and Reimbursement Overview
16 SOLID TUMORS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SOLID TUMORS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SOLID TUMORS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
